Clinical Trials Logo

Muscle Weakness clinical trials

View clinical trials related to Muscle Weakness.

Filter by:

NCT ID: NCT04234282 Recruiting - Knee Osteoarthritis Clinical Trials

Rate of Torque Development and Voluntary Quadriceps Activation in Patients With Knee Osteoarthritis: A Quantitative Analysis Before and After a Single Session of Manual Physical Therapy

Start date: January 2020
Phase: N/A
Study type: Interventional

This is a randomized control trial to determine if there is a measurable change in voluntary quadriceps activation, RTD, pain, and function before and after a single session of manual physical therapy. The researchers will utilize a sample of convenience with consecutive sampling at the Brooke Army Medical Center physical therapy clinic for patients referred for knee osteoarthritis. As is standard of care, patients will be provided a medical intake form and a clinical outcome measure commensurate with their primary anatomic region for which they are seeking physical therapy (i.e.: Lower Extremity Functional Scale for hip, knee, or ankle pain). If patients choose to partake in the study, they will complete the consent form and the initial physical therapy evaluation will be conducted. They will then be provided an appointment for data collection at the Army-Baylor Center for Rehabilitation Research biomechanics lab at the Army Medical Department Center and School. The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The control group will receive a 30-minute class on knee OA diagnosis, prognosis, various treatment options, and will conclude with a question and answer with the researcher. Both groups will receive their intervention from a board-certified physical therapist in the Army-Baylor Orthopedic Manual Therapy Fellowship program. At the conclusion of formal testing, the patient will be provided standard physical therapy care as deemed appropriate by their evaluating physical therapist. Thus, all subjects, regardless of their assigned group, will receive the same standard of care for their knee pain.

NCT ID: NCT04226170 Recruiting - Myasthenia Gravis Clinical Trials

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Start date: April 8, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

NCT ID: NCT04225871 Active, not recruiting - Clinical trials for Generalized Myasthenia Gravis

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

RAISE-XT
Start date: December 23, 2019
Phase: Phase 3
Study type: Interventional

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

NCT ID: NCT04224506 Recruiting - Myasthenia Gravis Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04207359 Completed - Breast Cancer Clinical Trials

Effects of Creatine Supplementation in Breast Cancer Survivors

Start date: September 30, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to test the hypothesis that creatine will accelerate adaptations associated with exercise in breast cancer survivors recently completing chemotherapy.

NCT ID: NCT04202341 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Start date: December 2, 2019
Phase:
Study type: Observational [Patient Registry]

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

NCT ID: NCT04199312 Recruiting - Muscle Weakness Clinical Trials

Magnetic Muscle Stimulation of Abdominal Muscle

MMS
Start date: November 4, 2019
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of magnetic muscle stimulation (MMS) of abdominal muscle.

NCT ID: NCT04182984 Recruiting - Clinical trials for Ocular Myasthenia Gravis

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

TREAT-OMG
Start date: November 4, 2019
Phase:
Study type: Observational [Patient Registry]

This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).

NCT ID: NCT04181671 Completed - Clinical trials for Muscle Weakness Condition

Low Resistance Venous Blood Flow Restriction Training (LR-VBFRT) on Biceps Brachii Muscle Performance

Start date: November 4, 2019
Phase: N/A
Study type: Interventional

Resistance training has been widely recognized as an effective stimulus for increasing skeletal muscle size and strength. This study intends to compare the effects of high resistance training without blood flow restriction and the low resistance training with blood flow restriction training on bicep muscle performance.

NCT ID: NCT04176211 Completed - Myasthenia Gravis Clinical Trials

The Impact of Myasthenia Gravis in the Real World

Start date: December 12, 2019
Phase:
Study type: Observational [Patient Registry]

An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's natural history, its burden on patients and their families, its treatment, as well as its medical, social and pharmacoeconomic impact.